Second clinical trial on the use of BioCurcumin in people with depression

September 05, 2014

Second clinical trial on the use of BioCurcumin in people with depression

     The following evidence is from a state of the art, gold standard, randomized, placebo-controlled, clinical trial; the best level of evidence for a study. It was performed at the School of Psychology and Exercise Science, Murdoch University, Perth, Western Australia. Fifty-six patients with major depressive disorder suffering with symptoms at the time of the study were randomly split into a placebo group and a treatment group. The treatment group received BioCurcumin at a dosage of 500mg twice a day with meals for eight weeks. 

Within the fourth week the patients on BioCurcumin were already reporting significant drops on symptoms of depression and anxiety compared with those on placebo which continued to improve over the course of the study. In patients with atypical depression, which is a subtype of major depressive disorder that is even more difficult to treat, the effects were even better for depression and anxiety. This form of depression is associated with higher levels of inflammation in the brain. The BioCurcumin improved every score of depression significantly save one and this one still had a positive trend for benefit. The study is published in the October 1st, 2014 issue of the Journal of Affective Disorders.

Here is our previous posting of the other human clinical trial using BioCurcumin in patients with depression from August of last year;


BioCurcumin may work in depression

     A recently published clinical trial shows that BioCurcumin works as well as fluoxetine (generic Prozac) in patients with severe depression. In this study sixty patients with major depressive disorder (MDD) were split into 3 groups of 20. They received BioCurcumin 500 mg capsules twice daily; fluoxetine 20 mg daily, or the combination of BioCurcumin with fluoxetine.

Results were assessed using the clinically validated Hamilton Rating Scale for Depression (HAM-D17 scale). This scale is used to rate the severity of depression by evaluating mood, feelings of guilt, suicide ideation, insomnia, agitation or motor retardation, anxiety, weight loss, and other somatic (physical) symptoms.

All three groups had good improvement in their level of depression. The proportion of responders as measured by the HAM-D17 scale was higher in the combination group (78 %) than in the fluoxetine (65 %) and the curcumin (63 %) groups, however, these data were not statistically significant (clinically meaningful) from one another. Therefore, the BCM-95 Curcumin worked basically as well as the prescription drug fluoxetine in terms of changes in the HAM-D17 score from baseline to six weeks of treatment. This study provides the first human clinical indication that curcumin may be used as an effective and safe treatment for patients with MDD without concurrent suicidal ideation or other psychotic disorders.

BioCurcumin is absorbed 7 to 10 times better than plain curcumin and has been the subject of 13 published studies with many more on the way. As reported by the PRNewswire, in Dallas on July 11, 2013 When asked how curcumin is applicable to depression, Dr. Ajay Goel, of the Baylor Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center and study co-author, stated, "It is a novel and surprising application for this natural medicine. People with depression have higher levels of inflammation in the brain. Also, people with depression have lower levels of neurogenesis in the brain, meaning they make fewer new brain cells than people with no history of depression. Curcumin is both a potent anti-inflammatory agent and a powerful stimulator for neurogenesis. A recent animal study was published on BioCurcumin compared to both fluoxetine and imipramine (an older class of antidepressant medications) and showed excellent results. We are excited to learn the effectiveness of BCM-95 Curcumin in a human study."

When asked about the importance of this study, Dr. Goel replied, "Depression is a major global public health issue leading to substantial disability. The pharmaceutical interventions can be quite costly, and have many potentially serious adverse effects. There are also many people whose disease does not fully respond to treatment. The BioCurcumin used in this study shows efficacy on major depression on its own at the same level as the drug, and even better results when combined with the drug. This may be meaningful for the health of millions of people." The study was made available online in July in advance of publication in the journal Phytotherapy Research.

Ajay Goel, Ph.D., is Director of Epigenetics and Cancer Prevention at Baylor University Medical Center in Dallas, TX. He has spent more than 20 years researching cancer and has been the lead author or contributor to over 150 scientific articles published in peer reviewed international journals and several book chapters. He is currently researching the prevention of gastrointestinal cancers using integrative and alternative approaches, including botanical products. Two of the primary botanicals he is investigating are curcumin (from turmeric) and boswellia.

Dr. Goel is also a member of the American Association for Cancer Research and the American Gastroenterology Association and is on the international editorial boards of Gastroenterology, Clinical Cancer Research, PLoS One, Digestive Diseases and Sciences and World Journal of Gastrointestinal Oncology. He also performs peer-reviewing activities for almost 75 scientific journals, as well as serves on various grant funding committees of the National Institutes of Health.